These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 14499309

  • 1. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis.
    Maclean R, Ward PE, Glen I, Roberts SJ, Ross BM.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):927-33. PubMed ID: 14499309
    [Abstract] [Full Text] [Related]

  • 2. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry.
    Ross BM, Hughes B, Turenne S, Seeman M, Warsh JJ.
    Eur Neuropsychopharmacol; 2004 May; 14(3):191-7. PubMed ID: 15056478
    [Abstract] [Full Text] [Related]

  • 3. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.
    Smesny S, Rosburg T, Riemann S, Baur K, Rudolph N, Berger G, Sauer H.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jun; 72(6):393-402. PubMed ID: 15885994
    [Abstract] [Full Text] [Related]

  • 4. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking.
    Liu CM, Chang SS, Liao SC, Hwang TJ, Shieh MH, Liu SK, Chen WJ, Hwu HG.
    Psychiatry Res; 2007 Aug 30; 152(2-3):181-7. PubMed ID: 17459487
    [Abstract] [Full Text] [Related]

  • 5. Alterations of niacin skin sensitivity in recurrent unipolar depressive disorder.
    Smesny S, Baur K, Rudolph N, Nenadic I, Sauer H.
    J Affect Disord; 2010 Aug 30; 124(3):335-40. PubMed ID: 20116108
    [Abstract] [Full Text] [Related]

  • 6. Phospholipid membrane abnormalities and reduced niacin skin flush response in schizophrenia.
    Buretić-Tomljanović A, Giacometti J, Nadalin S, Rubesa G, Vulin M, Tomljanović D.
    Psychiatr Danub; 2008 Sep 30; 20(3):372-83. PubMed ID: 18827766
    [Abstract] [Full Text] [Related]

  • 7. Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis.
    Glahn DC, Bearden CE, Cakir S, Barrett JA, Najt P, Serap Monkul E, Maples N, Velligan DI, Soares JC.
    Bipolar Disord; 2006 Apr 30; 8(2):117-23. PubMed ID: 16542181
    [Abstract] [Full Text] [Related]

  • 8. Methylnicotinate stimulated prostaglandin synthesis in patients with schizophrenia: A preliminary investigation.
    Ross BM.
    Prostaglandins Leukot Essent Fatty Acids; 2018 Sep 30; 136():99-102. PubMed ID: 28552466
    [Abstract] [Full Text] [Related]

  • 9. Hyperprolinemia is a risk factor for schizoaffective disorder.
    Jacquet H, Demily C, Houy E, Hecketsweiler B, Bou J, Raux G, Lerond J, Allio G, Haouzir S, Tillaux A, Bellegou C, Fouldrin G, Delamillieure P, Ménard JF, Dollfus S, D'Amato T, Petit M, Thibaut F, Frébourg T, Campion D.
    Mol Psychiatry; 2005 May 30; 10(5):479-85. PubMed ID: 15494707
    [Abstract] [Full Text] [Related]

  • 10. Niacin skin flush test: a research tool for studying schizophrenia.
    Nadalin S, Buretić-Tomljanović A, Rubesa G, Tomljanović D, Gudelj L.
    Psychiatr Danub; 2010 Mar 30; 22(1):14-27. PubMed ID: 20305586
    [Abstract] [Full Text] [Related]

  • 11. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia.
    Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, Kapczinski F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct 01; 32(7):1677-81. PubMed ID: 18657586
    [Abstract] [Full Text] [Related]

  • 12. Investigating the association between neurocognition and psychosis in bipolar disorder: further evidence for the overlap with schizophrenia.
    Jabben N, Arts B, Krabbendam L, van Os J.
    Bipolar Disord; 2009 Mar 01; 11(2):166-77. PubMed ID: 19267699
    [Abstract] [Full Text] [Related]

  • 13. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia.
    Sánchez-Morla EM, García-Jiménez MA, Barabash A, Martínez-Vizcaíno V, Mena J, Cabranes-Díaz JA, Baca-Baldomero E, Santos JL.
    Acta Psychiatr Scand; 2008 Apr 01; 117(4):313-8. PubMed ID: 18241306
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The niacin skin flush test in schizophrenia: a replication study.
    Puri BK, Easton T, Das I, Kidane L, Richardson AJ.
    Int J Clin Pract; 2001 Apr 01; 55(6):368-70. PubMed ID: 11501224
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder.
    Dean B, Digney A, Sundram S, Thomas E, Scarr E.
    Psychiatry Res; 2008 Feb 28; 158(1):75-8. PubMed ID: 18096247
    [Abstract] [Full Text] [Related]

  • 18. Niacin sensitivity and the arachidonic acid pathway in schizophrenia.
    Messamore E, Hoffman WF, Yao JK.
    Schizophr Res; 2010 Sep 28; 122(1-3):248-56. PubMed ID: 20417059
    [Abstract] [Full Text] [Related]

  • 19. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model.
    Levine J, Sela BA, Osher Y, Belmaker RH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Sep 28; 29(7):1181-91. PubMed ID: 16115716
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.